-
ABOUT US
-
R&D
-
AGORA
-
PR
-
RECRUITMENT
-
CONTACT
R&D
R&D
Pipeline
Pipeline
Pipeline overview
Three H Bio (3H Bio) Co., Ltd., a Korean bio-venture company established in 2019. 3H Bio develops Obesity Vaccine (3HOTP) candidate and a series of first-in-class drugs for metabolic diseases, including Type 2 Diabetes Mellitus (T2DM) and Non-Alcoholic Fatty Liver Disease (NAFLD). Also, an organoid-based Developmental And Reproductive Toxicity (DART) drug-screening platform technology is under development.
3H Bio provides an exciting in-licensing opportunity for worldwide companies seeking new anti-obesity drugs and the drugs for metabolic syndromes related with lipid metabolism.
Drug development
| Indication | Program | Discovery | Non GMP study | IND | Phase1 |
|---|---|---|---|---|---|
| Obesity | 3HOTP (Human) |
|
|||
| 3HOTP (Veterinary) |
|
||||
| T2DM | 3HDTV |
|
|||
| NAFLD | 3HHTA |
|
|||
Toxicology evaluation platform
| Project | Proof-of-concept | Clinical evaluation | Marketing approval |
|---|---|---|---|
| Organoid-based prenatal tox evaluation platform |
|
||